Hints and tips:
Showing results for Floor v. Takeda Pharmaceuticals America Inc
Related Special Reports
...The US drugmaker has spent almost $30bn on acquisitions over the past two years, snapping up Arena Pharmaceuticals, Biohaven Pharmaceuticals, Global Blood Therapeutics, ReViral and Trillium Therapeutics....
...After she found out about the delays, Paris said that she “cried like a baby on the floor of my home because I dreaded the pain coming back”....
...The publicly traded real estate investment trust operates 41.9mn square feet of space in North America, with millions more in development. Its market capitalisation stands at $24bn....
...Tishman Speyer, one of New York’s largest commercial property developers, had previously secured pharmaceuticals company Pfizer as its anchor tenant for the Spiral....
...Half of the Spiral will become the new headquarters for Pfizer, the pharmaceuticals company at the Covid-19 vaccine vanguard. The rest remains to be leased....
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...Their concentrated ownership of industries such as airlines and pharmaceuticals may push up travel and drug prices, some academics argue....
...Here’s Bank of America: We had modelled £40m in our estimates and our sense is investors were factoring in £40-50m....
...The latest acquisition contributes to a record year for Japanese outbound deals, led by Takeda Pharmaceutical’s £46bn agreement to buy Irish drugmaker Shire in April....
...Others focused on the significance of Takeda’s move for its country’s pharmaceuticals industry....
...The company had just completed its first big live demonstration for a pharmaceutical company....
...The combined value of those deals — which include Takeda Pharmaceutical’s ¥7tn planned takeover of Shire — was around ¥11.7tn....
...Corporate giants including US cable group Comcast, wireless provider T-Mobile and Japan’s pharmaceutical maker Takeda reached for M&A to head off competitive threats and expand their businesses....
...Separately, Japan’s Takeda Pharmaceutical has reached a preliminary agreement to buy Irish drugmaker Shire for about £46bn, a deal that could spark a renewed wave of “big pharma” deals....
...As OxyContin flooded America — with more than 51m prescriptions written between 2006 and 2015 — legitimate patients became addicted to the painkiller....
...Hebei Welcome and other vitamin C exporters would be less vulnerable to anti-dumping charges if they all agreed to set prices above an agreed floor....
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...In the latest sign of how eager boardrooms are sparking a record number of “megadeals”, Japan’s top drugmaker Takeda revealed it was weighing a $40bn takeover of Irish rival Shire....
...On a recent trip to Arizona’s Canyon de Chelly, I took a very bumpy Jeep tour along its sandy floor....
...Separately, Hikma disclosed on Thursday that it will expand its licensing and distribution pact with Japan’s Takeda Pharmaceuticals that will add new products to its Middle East and North Africa portfolio...
...(Special Projects Desk) News round-up Shire board recommends £46bn takeover by Takeda (FT) How Disney could avoid a Fox bidding war against Comcast (CNBC) Standard Life Aberdeen fights Lloyds to keep...
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...When De La Rosa encountered it in 2012, America was awash with opioid painkillers....
...Thomas Sheehan, head of global healthcare at Bank of America Merrill Lynch, said despite the slowdown the fundamentals for dealmaking remained unchanged and activity was bound to pick up again....
...Cancer drug maker Takeda Pharmaceutical, fell 2.6 per cent following Trump’s comments....
International Edition